Grifols (GRFS) Change in Cash (2009 - 2020)
Grifols' (GRFS) quarterly Change in Cash came in at -$5.9 million in Q4 2016, up 95.67% YoY from -$3.0 million in Q1 2016, and up 99.09% on a QoQ basis from -$644.6 million in Q3 2016.
Grifols (GRFS) Change in Cash (2009 - 2020) Analysis & Trends
Grifols (GRFS) has 8 years of Change in Cash data on file, last reported at -$5.9 million in Q4 2016.
- Quarterly Change in Cash rose 95.67% year-over-year to -$5.9 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$901.1 million (down 1520.11% YoY) and the FY2025 annual result came in at -$180.4 million, down 137.44% from the prior year.
- Change in Cash climbed to -$5.9 million in Q4 2016, from -$644.6 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $631.9 million in Q2 2015 to a low of -$644.6 million in Q3 2016.
- A 5-year average of -$4.5 million and a median of -$2.8 million in 2012 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2013 — Change in Cash soared 39081.59% — and 2015, when it plunged 1059.4%.
- Tracing GRFS's Change in Cash over 5 years: stood at $94.3 million in 2012, then jumped by 218.2% to $300.1 million in 2013, then sank by 186.85% to -$260.7 million in 2014, then surged by 47.88% to -$135.9 million in 2015, then surged by 95.67% to -$5.9 million in 2016.
- The last three Change in Cash figures came in at -$5.9 million (Q4 2016), -$644.6 million (Q3 2016), and -$135.9 million (Q4 2015), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.49 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 739.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.45 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -727.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -8.76 Mn |
| Dec 31, 2019 | -59.70 Mn |
| Mar 31, 2019 | -478.88 Mn |
| Dec 31, 2018 | 287.63 Mn |
| Jun 30, 2018 | -265.87 Mn |
| Mar 31, 2018 | 5.84 Mn |
| Dec 31, 2017 | 1.84 Bn |
| Jun 30, 2017 | -1.72 Bn |
| Mar 31, 2017 | 1.83 Bn |
| Dec 31, 2016 | -5.89 Mn |
| Sep 30, 2016 | -644.62 Mn |
| Dec 31, 2015 | -135.86 Mn |
| Sep 30, 2015 | -114.69 Mn |
| Jun 30, 2015 | 631.90 Mn |
| Mar 31, 2015 | -317.90 Mn |
| Dec 31, 2014 | -260.66 Mn |
| Sep 30, 2014 | 277.27 Mn |
| Jun 30, 2014 | -33.13 Mn |
| Mar 31, 2014 | 33.14 Mn |
| Dec 31, 2013 | 300.12 Mn |